CD8A and adenocarcinoma: Accordingly, the reduced development of both B16–F10 melanoma and TRAMP-C1 adenocarcinoma tumors have been reported in the preclinical models of PKCη defective Tregs, in association with a less immunosuppressive TME, increased the frequency and functionality of tumor-infiltrating CD8+ effector T cells and an elevated expression of CD86 on intra-tumoral DCs.